Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash & Equivalents (2022 - 2026)

Lexeo Therapeutics' Cash & Equivalents history spans 2 years, with the latest figure at $121.5 million for Q4 2023.

  • On a quarterly basis, Cash & Equivalents rose 57.06% to $121.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $121.5 million, a 57.06% increase, with the full-year FY2023 number at $121.5 million, up 57.06% from a year prior.
  • Cash & Equivalents hit $121.5 million in Q4 2023 for Lexeo Therapeutics, up from $35.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for LXEO hit a ceiling of $121.5 million in Q4 2023 and a floor of $35.4 million in Q3 2023.